Your Name:	Yijie Ma.
Manuscript Title	e:Megestrol acetate with a 5-HT3 receptor antagonist and dexamethasone can control chemother
induced nausea	and vomiting: a randomized controlled study
Manuscript nun	nber (if known):
	of transparency, we ask you to disclose all relationships/activities/interests listed below that are
	ontent of your manuscript. "Related" means any relation with for-profit or not-for-profit third

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initi	al planning of the work
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas None	t 36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	<u>X</u> None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	None	
	and the boston	and supplied the first	you referred about or the second
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	None	

None.		
	property in the second second	

Please place an "X" next to the following statement to indicate your agreement:

Your Name:	Weijie Zhao.
	legestrol acetate with a 5-HT3 receptor antagonist and dexamethasone can control chemotherage
	d vomiting: a randomized controlled study
Manuscript numbe	
related to the contr parties whose inter to transparency and	cansparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third rests may be affected by the content of the manuscript. Disclosure represents a commitment d does not necessarily indicate a bias. If you are in doubt about whether to list a cy/interest, it is preferable that you do so.
the following quest nanuscript only.	tions apply to the author's relationships/activities/interests as they relate to the current
item #1 below, re	y of hypertension, you should declare all relationships with manufacturers of antihypertensive that medication is not mentioned in the manuscript. Export all support for the work reported in this manuscript without time limit. For all other items, disclosure is the past 36 months. Name all entities with whom you have this relationship or indicate Specifications/Comments (e.g., if payments were made to you or to your institution)
	none (add rows as needed)
	Time frame: Since the initial planning of the work
All support for the manuscript (e.g., f provision of study medical writing, a processing charge No time limit for t	e present None funding, materials, rticle s, etc.)
	Time frame: past 36 months
Grants or contract any entity (if not in in item #1 above).	ndicated None
any entity (if not in	ndicated None

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	None	a destruction de la company de
	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	None	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	teo o los manuación allebas dime livar escal e
	Stock or stock options	_X_None	,
	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
	Other financial or non- inancial interests	None	

	none.			
and the same				

Please place an "X" next to the following statement to indicate your agreement:

Date: 7522.7,28.	
Your Name: VONY M Dow Manuscript Title: Megestrol acetate with a 5-HT3 receptor an	tagonist and dexamethasone can control chemotherapy
Manuscript Title: Megestrol acetate with a 5-HT3 receptor an	tagonist and devante
induced nausea and vomiting: a randomized controlled study	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame Since the mit	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Grants or contracts from any entity (if not indicated in item #1 above).	None	st 36 months
Royalties or licenses	None	
Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
			and the second of the second o
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Noher.	

Please place an "X" next to the following statement to indicate your agreement:

Date: 2022.9,21	
Varia Namas (1.0 h VV	01
Your Name: // Lh VV	with a 5-HT3 receptor antagonist and dexamethasone can control chemotherapy
induced nausea and vomiting: a ran	domized controlled study
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initi	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: par	st 36 months
3	Royalties or licenses	None	
4	Consulting fees	None None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u>X</u> None	
6	Payment for expert testimony	_X_None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Mone.		

Please place an "X" next to the following statement to indicate your agreement:

induced nausea and vomitin	g: a randomized controlled	or antagonist and dexamethasone can control chemotherap study
Manuscript number (if know		
related to the content of your parties whose interests may	ur manuscript. "Related" me be affected by the content of necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a lo so.
The following questions app manuscript only.	ly to the author's relationsl	nips/activities/interests as they relate to the current
to the epidemiology of hype medication, even if that me	ertension, you should declar dication is not mentioned in support for the work report	e defined broadly. For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript. The manuscript without time limit. For all other items
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the init	aliplanning of the work
All support for the present manuscript (e.g., funding, provision of study material medical writing, article processing charges, etc.) No time limit for this item.	S,	
	Time frame: pa	s) 36 months
Grants or contracts from any entity (if not indicated in item #1 above).	None	
Royalties or licenses	None	
Consulting fees	None None	

5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_ <u>N</u> one	
	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	_ \(\Delta\) None	
0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
	Stock or stock options	None	
	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_ \overline None	
	Other financial or non- financial interests	_None	

None.	
Toone	

Please place an "X" next to the following statement to indicate your agreement:

Date:	bn.9.2	.\$·	
Your Name:	Chi	Zhana	
Manuscript Title	:Megestrol acet	ate with a 5-HT3 receptor antagonist and dexamethasone can control chemotherap	y -
induced nausea	and vomiting: a	randomized controlled study	
Manuscript num	ber (if known):_		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

200		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time traver Sincer training	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pasi	36 months
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	/ None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	_>_None	
-	Patents planned, issued or pending	None	
	Participation on a Data Safety Monitoring Board or Advisory Board	None	
The state of the state of the state of	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
	Stock or stock options	None	
v	Receipt of equipment, materials, drugs, medical writing, gifts or other ervices	None	
fi	Other financial or non- inancial interests	№ None	

None			

Please place an "X" next to the following statement to indicate your agreement:

9 20	
Date: 2522. 1, 4	
Date:	l chamatharany
Your Name: Nime V	ronist and dexamethasone can control chemotherapy-
Your Name: N/49 V) Manuscript Title: Megestrol acetate with a 5-HT3 receptor antagonal controlled study	(Onise area a suspension of the suspension of th
induced nausea and vomiting: a randomized controlled study	
Manuscript number (if known):	
Manuscript number (ii known).	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article processing charges, etc.) No time limit for this item.		
		,	
		Time frame: bas	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
1	Consulting fees	None	

	A Part of the Control		
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

None.	

Please place an "X" next to the following statement to indicate your agreement:

Your Name:	Suzia Luo.	
Manuscript Title: Megestrol	acetate with a 5-HT3 rece	ptor antagonist and dexamethasone can control chemotherapy
induced nausea and vomitin	ig: a randomized controlle	d study
Manuscript number (if know	vn):	
In the interest of transmission		
related to the content of ver	cy, we ask you to disclose	all relationships/activities/interests listed below that are
parties whose interacts may	ur manuscript. "Related" n	neans any relation with for-profit or not-for-profit third
to transparancy and does no	be affected by the conten	t of the manuscript. Disclosure represents a commitment
relationship/activity/interes	t necessarily indicate a bia	as. If you are in doubt about whether to list a
elationship/activity/interes	t, it is preferable that you	do so.
The following questions and	v to the author's relation	
nanuscript only.	y to the author's relations	ships/activities/interests as they relate to the current
A STATE OF THE STA		
he author's relationships la	ctivities/interacts ab and the	4.5.
o the epidemiology of hyper	rtension you should deale	defined broadly. For example, if your manuscript pertains
nedication, even if that med		
or and the control	reation is not mentioned in	n the manuscript.
n item #1 helow report all s		
he time frame for disclosure	upport for the work report	ted in this manuscript without time limit. For all other items,
and the for discipsure	is the past 36 months.	
	Name all entities with	Specification (C
	whom you have this	Specifications/Comments
	relationship or indicate	(e.g., if payments were made to you or to your institution)
	none (add rows as	motitudity
THE TARREST OF THE PROPERTY OF THE PARTY OF	needed)	
All	Tine tame since the min	al garming of the work
All support for the present	None	
manuscript (e.g., funding,		
provision of study materials,	·	
medical writing, article processing charges, etc.)		
No time limit for this item.		
time mint for this item.		
	2	
Grants or contracts from	Time frame pas	36 months
any entity (if not indicated	None	
in item #1 above).		
Royalties or licenses	None.	
	None	
Consulting fees	None	
	- INOHE	the state of the s

	Payment or honoraria for	None	
	Payment or honoraria for lectures, presentations, speakers bureaus,	P none	
	manuscript writing or educational events		
	Payment for expert testimony	None	
	Support for attending meetings and/or travel	None	
3	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

Todas surriva		2 1 2 2
None.		

Please place an "X" next to the following statement to indicate your agreement: